Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged Oral Etoposide in Advanced Ovarian and Cervical Cancer
NCT00002478Phase 2Terminated
- Sponsor
- GOG Foundation
- Start
- Jun 1993
- Primary completion
- Oct 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide in ovarian cancer and Cervical Cancer (CC), sponsored by GOG Foundation. Primary endpoint: Objective Response Rate up to 12 months. Started Jun 1993; status: terminated.
02
Drugs
etoposide
03
Conditions
ovarian cancerCervical Cancer (CC)
Beyond the preview
Go deeper on NCT00002478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002478.